Articles About Uncategorized

You Can Profit on Blockchain, Even During Bitcoin’s Wild Ride – Here’s How

0 | By Michael A. Robinson

On Jan. 9, the storied but beleaguered photography firm Eastman Kodak Co. (NYSE: KODK) let slip the word that it’s integrating blockchain technology into its operations.

Kodak said it wants to use the blockchain distributed ledger to help photographers license their work – and get paid – when people use those images.

You know what happened next…

Kodak’s shares soared higher by 119% that day – and then another 57% the next day.

Then the talking heads on CNBC and Fox Business – and in mainstream publications everywhere – tut-tutted both Kodak and the investors who bought into its scheme.

They’ve got a point – chasing after desperate companies putting blockchain into their business or names is a bit foolish. After all, plenty of investors who hit the greed pedal following Kodak’s blockchain announcement got creamed on profit-taking.

Here’s the thing. Those mainstream analysts missed the larger meaning behind this story.

Investors are right now feeling a great need to invest in blockchain before they miss their opportunity. And they’re chasing it everywhere they see it, even if it means making a play on a long-struggling company like Kodak.

The blockchain, of course, is the backend technology that makes cryptocurrencies like Bitcoin possible. And it’s the blockchain’s promise that’s behind Bitcoin’s and other digital coins’ recent wild ride.

So I get it. I want to be invested in blockchain- and I think you folks should be, too. But plays like Kodak are extremely risky trades, not long-term profitable investments.

So today I want to tell you about a stock that is a great backend play on blockchain technology.

It’s is a highly respected tech leader that offers stable returns – but that will crush the market over the next three years thanks to its moves into blockchain and other bleeding-edge technologies.

Let’s take a look…

My Top Biotech Play for 2018 Could Make You 110.5% in 12 Months – if You Act Now

0 | By Michael A. Robinson

Between Oct. 5 and Nov. 11, one of the bellwether biotech exchange-traded funds fell 10.5%.

That’s a correction, as defined by most market watchers.

And most investors – and their “enablers” on Wall Street – have shied away from biotech shares since. They’re jittery.

In fact, I saw one august financial publication -the highly respected Investor’s Business Daily – warn folks away from biotech in 2018 due to “median tenure of chief executives at large-cap biotech companies.”

That’s not just a stretch. It’s a load of malarkey.

Here’s the thing: If you want to double your money in 2018, you absolutely must invest in biotech.

66 Billion Reasons to Invest in India – Right Now

0 | By Michael A. Robinson

On Tuesday, we talked about a “Trump-proof” way to play China’s exploding social media and e-commerce markets.

I told you I would follow up soon with another tech-based “frontier” investment.

Today I’m keeping that promise.

With 1.3 billion residents, India is the globe’s second-most-populous nation. And it could surpass China in as little as five years.

India logged GDP growth of 7% in last year’s fourth quarter. That beat forecasts by 10%. Even if that were to slow by as much as 20%, India’s economy would still be expanding twice as fast as that of the United States.

In just the past decade, India’s $2.2 trillion economy has leapt past Italy, Brazil, Canada, South Korea, and Russia. That means it’s now the globe’s seventh-largest economy – and it could move up to fifth place by 2020.

That kind of growth makes India one of the most enticing frontier investing markets today. And we know high tech is set to play a central role in this massive opportunity.

While India has a rich history of economic and business growth, it’s equally well known for its “threat landscape.” Corruption, crime, political instability, and terrorism all scare away many investors.

That’s why I’ve searched high and low for a way to get in on India’s ferocious tech growth – a way to get on the sadak to wealth” – without exposing ourselves to those sorts of risks.

But that still offers hope of quick triple-digit gains…

And I’ve finally found it…

While Others Worry, You Can Profit

4 | By Michael A. Robinson

As the song goes, “You can’t always get what you want.”

This applies well to last week’s announcement of plans for full legalization of adult marijuana use in Canada. During that April 13 event, the Trudeau government said all will be in place by July 1, 2018.

But there was a “problem” – at least according to some legalization advocates and analysts.

Instead of laying everything out precisely, legalization in Canada is still evolving. For instance, individual Canadian provinces will have a lot of say about where and when marijuana can be sold, how old buyers can be, and taxation.

So there is much more work to do than was hinted by the government when it leaked preliminary legalization details back on March 27.

And out come the handwringers – fretting that legalization will be delayed or… maybe… never even happen.

Don’t join these worrywarts.

Nothing here shatters the lucrative reality that double-, triple, or even quadruple-digit gains are on the way for the five stocks I included my latest report – How to Make a Fast Fortune on Canada’s Upcoming Total Legalization of Marijuana.

In fact, there are four reasons why you don’t need to lose sleep.

Here they are…

Sometimes the Road to Wealth Is Paved by Tech – and Toothpaste

1 | By Michael A. Robinson

Even if your name is Bill Gates or Warren Buffet, $3 billion is a lot of money.

And even if you’re finding that the years fly by as you get older, 12 years is a long time.

Yet, on average, that’s what it takes for a biopharmaceutical company to develop a new drug from discovery stage to pharmacy shelves.

Moreover, the ratio of researched treatments to eventually approved therapies – at somewhere between 5,000-to-1 and 10,000-to-1 – may be even more depressing for drug developers.

However, if all goes as planned – if a drug makes it into your medicine cabinet – then they’ll make that money back… and more. Particularly if they come up with a real blockbuster.

But still, so much vital R&D money goes down the drain.

Little wonder then that a major drug player might want to realign its operations to be less focused on the boom-and bust cycle of drug research.

Today, we’ll explore a Big Pharma leader that’s doing just that.

It got started on this move three years ago.

It just made a big promotion that will serve as a further catalyst in this same direction.

And its stock could make you 20% a year – or more – for a long time to come.

Read on…

When Putting Money on the Line, There’s One Thing Worse Than “Fake News”

0 | By Michael A. Robinson

Ever since Donald Trump was sworn in as president, we’ve seen a lot of talk about “fake news.”

Depending on how you’re feeling on any given day, that’s either hoaxes, propaganda, and disinformation that isn’t true… or simply news you don’t like.

But there’s something else going on – in the world of investing – that’s even more dangerous.

I call it “incomplete news.”

See, the mainstream financial media would have you think that blindly following Wall Street’s march will put you on the road to wealth.

In reality, that’s a path to ho-hum returns.

You can do better.

Much better.

And I can prove it…

These Two Triggers Are About to Create Fast Fortunes for Cannabis Investors

2 | By Michael A. Robinson

Last week, I showed you just how profitable “frontier investing” can be.

It’s a deceptively simple, powerful approach I use to help my Nova-X Report readers make fast fortunes: Research a good investment, build a thesis, target the best stock before Wall Street analysts know it exists, and let the profits come to you as the crowd piles in.

Silicon Valley is a hotbed of this kind of investing – one where my readers have been able to make a killing. Biotech, rare earths, and cryptocurrencies are three others.

Cannabis investing is the latest and most profitable.

It’s easier now than it’s ever been to get wired into the growth of the legal marijuana sector.

And even after the sweep of states legalizing cannabis on Nov. 8, there’s plenty more of that growth on the way.

Today we’ll look at why that’s true.

And how you can get in on it…

What This Federal “Task Force” Means for Cannabis Investors

0 | By Michael A. Robinson

Sometimes it feels like panic is our new national pastime.

Smart investors like you, however, know better than to jerk their knee every time the mainstream media sensationalizes a story.

That said, I subscribe to the theory that an occasional reminder can be helpful.

Why I’m a Huge Fan of “Frontier Investing” in Pot Stocks

1 | By Michael A. Robinson

When most investors think of the booming legal cannabis sector, they don’t automatically think “high tech” or the life sciences.

That’s a mistake – a potentially costly one.

For one thing, cannabinoids can be used to treat all sorts of ailments, from cancer to arthritis to insomnia. Then there are all the high-tech applications exploding in the growth and consumption of legal marijuana.

But more importantly, cannabis investing is out on the “frontier.”

As you’ll see, that’s one of the most profitable places you can be…

Legal Cannabis’ Credibility Soars With Launch of First “Pot Stock” ETF

1 | By Michael A. Robinson

We’ve been looking at legal marijuana stocks a lot lately.

If you need a reminder as to why, well, look at this…

In 2013, the market for medically “sanctioned’ marijuana was worth about $1.5 billion. It’s expected to reach $6.7 billion this year – and $35 billion by 2020. And by 2029: The market is projected to reach $100 billion.

Those are hefty numbers.